Printer Friendly

rTMS investigated in autism spectrum disorder.

AT THE AACAP ANNUAL MEETING

SAN ANTONIO -- A technology currently approved to treat depression that is being investigated in a range of psychiatric disorders might be a viable treatment strategy to improve executive function in young people with autism spectrum disorder, based on the results of a pilot randomized double-blind trial of repetitive transcranial stimulation, or rTMS.

Impairments in executive function are common among higher-functioning people with ASD, and previous studies have found executive function impairments to have common neurobiologic underpinnings, Dr. Stephanie Ameis of the Campbell Family Mental Health Research Institute in Toronto said at the annual meeting of the American Academy of Child and Adolescent Psychiatry.

No studies to date have investigated rTMS on executive function in autism, but previous research by Dr. Ameis's colleague and coauthor on the study, Dr. Z. Jeff Daskalakis, found that a course of rTMS significantly improved executive function among people with schizophrenia (Biol Psychiatry. 2013;73[6]:510-7).

Dr. Ameis and her colleagues hypothesized that a similar treatment approach might be feasible in people with ASD with known executive function impairment.

The researchers randomized 18 patients aged 16-35 years to either 4 weeks of rTMS (20Hz) to the dorsolateral prefrontal cortex or sham treatment. All subjects were clinically stable, with an IQ greater than 70 (mean 95) and a qualifying measure of disability on the BRIEF (Behavior Rating Inventory of Executive Functions) assessment tool used to measure real world impairment.

MRI and cognitive assessment were performed at baseline and 1 month after the treatment period ended. Baseline analysis of diffusion MRI indicated a trend toward a significant positive association between working memory scores on the BRIEF and white matter structures along the anterior thalamic region. Though white matter integrity in this part of the brain has been linked to executive function in other disorders, Dr. Ameis cautioned that the MRI findings in her study were preliminary and that it was too early to draw conclusions from them.

The mean age in the study was 23 years. Dr. Ameis said she hopes to continue to recruit a younger cohort, but that recruitment challenges led the group to expand an initial targeted age range of 16-25 years up to 35 years.

"We want to focus our intervention on the transition period to adulthood, as this is a time where effective interventions can really make an impact on individuals' successful transition to work and school as young adults."

The goal, Dr. Ameis said, "is to see if rTMS is feasible for this particular indication or treatment target, and so it's the first study that's really used a rigorous sham study design for this indication. We're seeing whether people are interested and able to tolerate the 4-week protocol, as well as the other aspects of our study and secondarily, whether we are changing things with regard to [executive function]."

The protocol was well tolerated, the researchers found, with the time commitment--about 30 minutes a day, 5 days a week--being the biggest demand on subjects. rTMS was associated with no adverse effects except headaches around treatment times.

The pilot study established tolerability and feasibility in this patient group, Dr. Ameis said. Now the investigators will measure differences in executive function after a second year of recruitment to double the current sample size.

Dr. Ameis reported no conflicts of interest related to the findings. A coauthor on the study, Dr. Paul E. Croarkin, reported funding from Pfizer, and study supplies and genotyping from Assurex. Dr. Daskalakis acknowledged funding from Neuronetics.

cpnews@frontlinemedcom.com

----------

Please note: Illustration(s) are not available due to copyright restrictions.
COPYRIGHT 2016 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CHILD/ADOLESCENT PSYCHIATRY
Author:Smith, Jennie
Publication:Clinical Psychiatry News
Date:Feb 1, 2016
Words:596
Previous Article:ASD prevalence lower in 4-year-olds than 8-year-olds.
Next Article:Coping difficulties, shyness are features of anxiety.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters